netFormulary

Alendronic Acid

First Choice

Approved alendronic acid formulations include:
- 10mg tablets (taken daily)
- 70mg tablets (taken once weekly) – preferred
- 70mg effervescent tablets (Binosto®) - for use only in patients with documented swallowing difficulties
Alendronic acid is approved for the primary prevention of osteoporosis in postmenopausal women in line with NICE
Approved for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis primary in line with NICE.
Approved for the treatment of osteoporosis in line with NICE

Disodium Pamidronate 30mg injection

Formulary

Ibandronic Acid

Formulary

Ibandronic acid 50mg tablets are approved for use in the reduction of bone damage in patients with metastatic breast cancer. Not approved for use in the treatment of patients with other forms of cancer (e.g. prostate).

Ibandronic acid 150mg tablets are approved for the treatment of osteoporosis in line with NICE

Ibandronic acid 3mg in 3ml injection is approved for use where oral bisphosphonates are not appropriate (not tolerated, contra-indicated because of upper gastro-intestinal problems or insufficiently effective)

Risedronate

Formulary

Approved risedronate formulations include:
- 5mg tablets (taken daily);
- 35mg tablets (taken once weekly for osteoporosis) -preferred.
Risedronate is approved for the primary prevention of osteoporosis in line with NICE, and for for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis in line with NICE.
Risedronate 30mg tablets are also approved for Paget’s disease.
Approved for the treatment of osteoporosis in line with NICE

Sodium Clodronate

Formulary

Zoledronic Acid 4mg injection

Formulary

Approved for use in treating hypercalcaemia of malignancy and the prevention of skeletal events in patients with metastatic breast cancer.
Approved for the adjuvant treatment of post-menopausal women with early breast cancer (subject to agreement with the CCGs and provider trusts regarding the extra activity).
Not approved for preventing skeletal events in patients with prostate cancer.
To avoid confusion it is recommended that this product is prescribed by brand name i.e. Zometa®

Zoledronic Acid 5mg injection

Formulary